Kester Capital has acquired EMAS Pharma, the clinical development division of Bionical Emas, alongside an experienced incoming executive team. EMAS Pharma is a leading Clinical Research Organisation, providing specialised services to the global pharmaceutical and biotech sectors.
 
Headquartered in the UK, EMAS Pharma offers market-leading expertise across multiple therapeutic areas, including oncology, rare diseases, inflammation, immunology and microbiome therapeutics. The business counts several of the largest and most innovative global pharma and biotech companies as long-standing customers. 

A brief note to say a huge thank you for all your support on Project Barcelona over the past few months. We appreciate it wasn’t straightforward at all, and you did a great job in a short space of time. We look forward to working with you all again soon. 
David Fernie, Vice President, Kester Capital LLP